QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pirgon, O. Articles by Sert, A. Search for Related Content PubMed PubMed Citation Articles by Pirgon, O. Articles by Sert, A.

Psoriasis Following Growth Hormone Therapy in a Child

Assistant Professor, Faculty of Medicine, Department of Pediatric Endocrinology, Selcuk University, Konya, Turkey

Mehmet Emre Atabek, MD

Professor, Faculty of Medicine, Department of Pediatric Endocrinology, Selcuk University

Ahmet Sert, MD

Assistant Professor, Faculty of Medicine, Department of Pediatric Endocrinology, Selcuk University

Reprints: Dr. Pirgon, Faculty of Medicine, Department of Pediatric Endocrinology, Selcuk University, 42080 Konya, Turkey, fax 00-90-332-223 6181, ozpirgon{at}hotmail.com

OBJECTIVE: To report a case of psoriasis that developed following growth hormone treatment.

CASE SUMMARY: An 8-year-old boy was admitted to our pediatric endocrinology department because of short stature (<3rd percentile). A dopamine stimulation test and an insulin tolerance test revealed growth hormone (GH) deficiency with a normal cortisol response. His insulin-like growth factor 1 (IGF-1) level (9 ng/mL; reference range 113–261) was under the limits for his age and sex. Six months after the initiation of treatment with recombinant human GH 0.33 mg/kg/wk, the patient presented with a 10 day history of desquamation and a burning sensation in his right knee and hip. Lesions of erythematous papules consistent with plaques of psoriasis were present. Histologic findings from skin biopsies were consistent with psoriasis. The GH dose was reduced to 0.2 mg/kg/wk and treatment for psoriasis (including hydrocortisone and clemastine) was started. Three months after those interventions, the plaques had resolved.

DISCUSSION: Previous studies proposed that the extent and severity of psoriasis correlate with GH levels, although psoriatic patients, in general, have normal GH and IGF-1 levels. The Naranjo probability scale indicated that the development of psoriasis was probably associated with GH therapy.

CONCLUSIONS: This case suggests that the development of psoriasiform lesions in a previously unaffected individual represents an adverse effect of GH treatment, occurring at higher doses, with higher IGF-1 levels.

Key Words: growth hormone, insulin-like growth factor 1, psoriasis

Published Online, December 19, 2006. www.theannals.com, DOI 10.1345/aph.1H324

This article has been cited by other articles:

				A. F. Moore, T. Soper, N. Jones, J. Grevelink, and N. Abourizk Psoriatic Exacerbation Associated With Insulin Therapy Diabetes Care, May 1, 2008; 31(5): e31 - e31. [Full Text] [PDF]